Human IGF-I/IGF-1 Antibody

Catalog #: MAB2912
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB2912-100
MAB2912-SP

Cell Proliferation Induced by IGF-I/IGF-1 and Neutralization by Human IGF-I/IGF-1 Antibody.

1 Image

All IGF-I/IGF-1 Antibodies

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IGF-I/IGF-1 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IGF-I/IGF-1 in direct ELISAs.

Source

Monoclonal Rat IgG_2A Clone # 997121

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant human IGF-I/IGF-1
Gly49-Ala118
Accession # P05019

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IGF-I/IGF-1-induced proliferation in the MCF‑7 human breast cancer cell line. Karey, K.P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND₅₀) is typically 0.1-0.8 µg/mL in the presence of 10 ng/mL Recombinant Human IGF-I/IGF-1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Proliferation Induced by IGF-I/IGF-1 and Neutralization by Human IGF-I/IGF-1 Antibody. Recombinant Human IGF-I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IGF-I/IGF-1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Human IGF-I/IGF-1 Monoclonal Antibody (Catalog # MAB2912). The ND₅₀ is typically 0.1-0.8 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGF-I/IGF-1

Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature human IGF‑I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively (2), and exhibits cross-species activity. It shares 64% aa sequence identity with mature human
IGF‑II. Circulating IGF‑I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4-7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF‑I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I association with IGF binding proteins increases its plasma half‑life and modulates its interactions with receptors (10).

References

Philippou, A. et al. (2007) In Vivo 21:45.
Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.

Long Name

Insulin-like Growth Factor I/Insulin-like Growth Factor 1

Entrez Gene IDs

3479 (Human); 16000 (Mouse); 24482 (Rat)

Alternate Names

IBP1; IGF1; IGF-1; IGF1A; IGFI; IGF-I; IGF-IA; IGF-IB; insulin-like growth factor 1 (somatomedin C); insulin-like growth factor 1; insulin-like growth factor I; insulin-like growth factor IA; insulin-like growth factor IB; Mechano growth factor; MGF; Somatomedin A; Somatomedin C; somatomedin-C

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citation for Human IGF-I/IGF-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Authors: C Sorrentino, L D'Antonio, SL Ciummo, C Fieni, L Landuzzi, F Ruzzi, S Vespa, P Lanuti, LV Lotti, PL Lollini, E Di Carlo
Journal of hematology & oncology, 2022-10-13;15(1):145.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization